5. Conclusion
T2D
Early short-term insulin treatment in newly diagnosed treatment-naïve T2D patients improves beta cell function more than long-term therapy with glimepiride, as reflected in C-peptide response to standardized test meal. Limited insulin intervention added to metformin is superior to glimepiride and metformin treatment regarding glycemic and lipid control. Legacy of its benefits extends to after the intervention duration, without a negative impact on body weight. Convenient insight into beta cell capacity at diagnosis and its response to treatment through a standardized test meal may guide individual approach amidst the known heterogeneity of T2D patients.
None of the authors have any conflicts of interest that may have influenced either the conduct or the presentation of the research.
Study protocol received institutional review board approval and all participants provided informed consent in the format required by the relevant authorities. (Approved by Ethics Board of Zvezdara University Medical Center, Decision dated 29.01.2019.)